Literature DB >> 31215845

Prognostic markers of lymphoma development in primary Sjögren syndrome.

S Retamozo1,2,3, P Brito-Zerón3,4, M Ramos-Casals3,5,6.   

Abstract

Sjögren syndrome is a systemic autoimmune disease that principally affects women between the fourth and sixth decades of life who present with sicca symptomatology caused by dryness of the main mucosal surfaces. The clinical spectrum of Sjögren syndrome extends from dryness to systemic involvement. Since 1978, Sjögren syndrome has been closely associated with an enhanced risk of lymphoma, one of the most severe complications a patient may develop. Primary Sjögren syndrome patients have a 10-44-fold greater risk of lymphoma than healthy individuals, higher than that reported for systemic lupus erythematosus and rheumatoid arthritis. The close link between lymphoma and Sjögren syndrome is clearly exemplified by the very specific type of lymphoma arising in Sjögren syndrome patients, mainly low-grade B-cell lymphomas (predominantly a marginal zone histological type) with primary extranodal involvement of the major salivary glands (overwhelmingly parotid), with a primordial role of cryoglobulinemic-related markers (both clinical and immunological). The most recent studies support a higher number of risk factors detected in an individual leads to a higher lymphoma risk. A close follow-up of high-risk groups with longitudinal assessments of all known risk factors, including cryoglobulin-related markers and EULAR Sjögren's syndrome disease activity index measurement in particular, is mandatory.

Entities:  

Keywords:  Lymphoma; Sjögren’s syndrome; prognostic markers

Mesh:

Substances:

Year:  2019        PMID: 31215845     DOI: 10.1177/0961203319857132

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  15 in total

1.  Prevalence and clinical presentation of lymphoproliferative disorder in patients with primary Sjögren's syndrome.

Authors:  Agata Sebastian; Marta Madej; Maciej Sebastian; Aleksandra Butrym; Patryk Woytala; Agnieszka Hałoń; Piotr Wiland
Journal:  Rheumatol Int       Date:  2020-02-01       Impact factor: 2.631

2.  Incidence of cancer in a cohort of patients with primary Sjögren syndrome in Argentina.

Authors:  Martin Brom; Sebastian Moyano; Ignacio J Gandino; Marina Scolnik; Enrique R Soriano
Journal:  Rheumatol Int       Date:  2019-08-30       Impact factor: 2.631

Review 3.  Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives.

Authors:  Dominic Kaddu-Mulindwa; Lorenz Thurner; Konstantinos Christofyllakis; Moritz Bewarder; Igor Age Kos
Journal:  Cancers (Basel)       Date:  2022-06-19       Impact factor: 6.575

4.  Normal-Appearing Salivary Gland Ultrasonography Identifies a Milder Phenotype of Primary Sjögren's Syndrome.

Authors:  Sara Zandonella Callegher; Alen Zabotti; Ivan Giovannini; Elena Treppo; Luca Quartuccio; Salvatore De Vita
Journal:  Front Med (Lausanne)       Date:  2020-12-09

5.  Primary Breast Extranodal Marginal Zone Lymphoma in Primary Sjögren Syndrome: Case Presentation and Relevant Literature.

Authors:  Giuseppe Ingravallo; Eugenio Maiorano; Marco Moschetta; Luisa Limongelli; Mauro Giuseppe Mastropasqua; Gisella Franca Agazzino; Vincenzo De Ruvo; Paola Tarantino; Gianfranco Favia; Saverio Capodiferro
Journal:  J Clin Med       Date:  2020-12-10       Impact factor: 4.241

6.  Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts.

Authors:  Vasileios C Pezoulas; Andreas Goules; Fanis Kalatzis; Luke Chatzis; Konstantina D Kourou; Aliki Venetsanopoulou; Themis P Exarchos; Saviana Gandolfo; Konstantinos Votis; Evi Zampeli; Jan Burmeister; Thorsten May; Manuel Marcelino Pérez; Iryna Lishchuk; Thymios Chondrogiannis; Vassiliki Andronikou; Theodora Varvarigou; Nenad Filipovic; Manolis Tsiknakis; Chiara Baldini; Michele Bombardieri; Hendrika Bootsma; Simon J Bowman; Muhammad Shahnawaz Soyfoo; Dorian Parisis; Christine Delporte; Valérie Devauchelle-Pensec; Jacques-Olivier Pers; Thomas Dörner; Elena Bartoloni; Roberto Gerli; Roberto Giacomelli; Roland Jonsson; Wan-Fai Ng; Roberta Priori; Manuel Ramos-Casals; Kathy Sivils; Fotini Skopouli; Witte Torsten; Joel A G van Roon; Mariette Xavier; Salvatore De Vita; Athanasios G Tzioufas; Dimitrios I Fotiadis
Journal:  Comput Struct Biotechnol J       Date:  2022-01-07       Impact factor: 7.271

7.  Increased Risk of Sjögren's Syndrome in Patients with Obsessive-Compulsive Disorder: A Nationwide Population-Based Cohort Study.

Authors:  Yi-Jung Chang; Jui-Cheng Tseng; Pui-Ying Leong; Yu-Hsun Wang; James Cheng-Chung Wei
Journal:  Int J Environ Res Public Health       Date:  2021-06-01       Impact factor: 3.390

Review 8.  Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients.

Authors:  Shuntaro Saito; Tsutomu Takeuchi
Journal:  J Clin Exp Hematop       Date:  2019

Review 9.  Understanding Fatigue in Sjögren's Syndrome: Outcome Measures, Biomarkers and Possible Interventions.

Authors:  Elisabeth Mæland; Samira T Miyamoto; Daniel Hammenfors; Valeria Valim; Malin V Jonsson
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

Review 10.  Shared Pathogenetic Features Between Common Variable Immunodeficiency and Sjögren's Syndrome: Clues for a Personalized Medicine.

Authors:  Luca Quartuccio; Ginevra De Marchi; Simone Longhino; Valeria Manfrè; Maria Teresa Rizzo; Saviana Gandolfo; Alberto Tommasini; Salvatore De Vita; Robert Fox
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.